Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung

• Literatur

• 1 Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immonol Methods 2005; 303: 81-91
• 2 Steiß JO, Schmidt A, Nährlich L et al. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Allergy Asthma Proc 2012; 33: 77-81
• 3 Strohner P, Staatz A, Sarrach D et al. The recoveryELISA – a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clin Chem Lab Med 2012; 50: 1263-1269
• 4 Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE mediated) asthma; PKPD analysis of a biomarker, total igE. Br J Clin Pharmacol 2011; 72: 306-320
• 5 Hanf G, Brachmann I, Kleine-Tebbe J et al. Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy 2007; 61: 1141-1144